While tremendous progress has been made in treating this disease,

While tremendous progress has been made in treating this disease, the evidence shows that we control the leukemia but do not cure these patients. Because they now live longer, patients face recurrent PR-171 in vivo relapses and can be confronted with the risk of cumulative immunosuppression as well as off-target effects

of therapy. The formation of an international organization – Hairy Cell Leukemia Research Foundation – dedicated to improving the outcome for these patients will enable a long-term assessment of quality of life issues. Establishment of an international clinical database will provide the ability to address issues relating to risks for infection, second malignancies, impact of treatment on fertility, employability, and other valuable measures, reflecting the benefit of participating in an organized clinical registry of a chronic disease. While we are pleased with the substantial improvement in outcomes for patients Bortezomib cell line who have benefitted from effective therapy, we need to understand and focus on the remaining unresolved issues that warrant

further clinical investigation. Long-term results are presented in Table 3. Despite considerable progress in understanding this disease, many interesting clinical and epidemiological questions remain. The opportunities for ongoing and new research in hairy cell leukemia are presented in Table 4. In fact, the Hairy Cell Leukemia 17-DMAG (Alvespimycin) HCl Research Foundation was established to address these issues in centers of excellence across the globe (www.hairycellleukemia.org). Dr.

Grever is a member of the Hairy Cell Leukemia Foundation, an entity mentioned in this manuscript. He serves as the Chairman of their Scientific Advisory Board and receives no compensation. This manuscript is dedicated to the memory of Dr. Bertha Bouroncle who died on August 16, 2013 in Columbus, Ohio. Dr. Bouroncle was an outstanding clinical investigator, educator, and physician who described the clinical entity of hairy cell leukemia in 1958. “
“The authors regret that the following error has occurred in the above article in Fig. 1 on page 113. The pKa values shown for cysteine and selenocysteine were mistakenly switched around in Fig. 1 on page 113. The correct pKa for Cys is 8.3, and that of Sec is 5.5. Please see below the corrected Fig. 1. “
“The publisher regrets that the following error has occurred in the article. In Table 3 on page 4, the value in the fourth column of probe set ID 1387093_at should have been 0.912 instead of −0.912. Please see below the corrected table. “
“The authors of the above paper would like to clarify the correct affiliation for the first author Steven Kuan-Hua Huan. Please see above the corrected affiliation. “
“This article has been removed: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been removed at the request of the Author.

Comments are closed.